Establishment and characterization of NCC-OS2-C1: a novel patient-derived cell line of osteosarcoma.

IF 3.1 3区生物学 Q3 CELL BIOLOGY Human Cell Pub Date : 2025-04-02 DOI:10.1007/s13577-025-01198-8

Shuhei Iwata, Rei Noguchi, Julia Osaki, Yuki Adachi, Yomogi Shiota, Koichi Ogura, Shogo Nishino, Akihiko Yoshida, Seiji Ohtori, Akira Kawai, Tadashi Kondo

{"title":"Establishment and characterization of NCC-OS2-C1: a novel patient-derived cell line of osteosarcoma.","authors":"Shuhei Iwata, Rei Noguchi, Julia Osaki, Yuki Adachi, Yomogi Shiota, Koichi Ogura, Shogo Nishino, Akihiko Yoshida, Seiji Ohtori, Akira Kawai, Tadashi Kondo","doi":"10.1007/s13577-025-01198-8","DOIUrl":null,"url":null,"abstract":"<p><p>Osteosarcoma is the most common primary bone sarcoma with a bimodal age distribution. Complete surgical resection with neoadjuvant chemotherapy is the standard curative treatment, and no effective therapeutic strategy has been established for metastatic cases, resulting in poor prognosis. Osteosarcoma presents complex and heterogeneous clinical and molecular features, and no molecular-targeted drugs are available. Therefore, effective multidisciplinary treatment strategies are urgently required. Patient-derived cell lines are essential tools in basic and translational oncology. Considering the heterogeneity of the disease, we established a novel cell line, NCC-OS2-C1, using surgically resected tumor tissues from a patient with osteosarcoma. NCC-OS2-C1 cells demonstrated constant proliferation, spheroid formation, and invasion. In addition, we demonstrated that NCC-OS2-C1 is applicable for the high-throughput screening of drugs. Thus, NCC-OS2-C1 is a valuable tool for basic and translational research on osteosarcoma.</p>","PeriodicalId":49194,"journal":{"name":"Human Cell","volume":"38 3","pages":"81"},"PeriodicalIF":3.1000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Cell","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s13577-025-01198-8","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Osteosarcoma is the most common primary bone sarcoma with a bimodal age distribution. Complete surgical resection with neoadjuvant chemotherapy is the standard curative treatment, and no effective therapeutic strategy has been established for metastatic cases, resulting in poor prognosis. Osteosarcoma presents complex and heterogeneous clinical and molecular features, and no molecular-targeted drugs are available. Therefore, effective multidisciplinary treatment strategies are urgently required. Patient-derived cell lines are essential tools in basic and translational oncology. Considering the heterogeneity of the disease, we established a novel cell line, NCC-OS2-C1, using surgically resected tumor tissues from a patient with osteosarcoma. NCC-OS2-C1 cells demonstrated constant proliferation, spheroid formation, and invasion. In addition, we demonstrated that NCC-OS2-C1 is applicable for the high-throughput screening of drugs. Thus, NCC-OS2-C1 is a valuable tool for basic and translational research on osteosarcoma.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

NCC-OS2-C1：一种新型骨肉瘤患者衍生细胞系的建立和特征描述。

骨肉瘤是最常见的原发性骨肉瘤，具有双峰年龄分布。完全手术切除加新辅助化疗是标准的治疗方法，对于转移病例尚未建立有效的治疗策略，导致预后较差。骨肉瘤具有复杂、异质性的临床和分子特征，目前尚无分子靶向药物。因此，迫切需要有效的多学科治疗策略。患者来源的细胞系是基础肿瘤学和转化肿瘤学的重要工具。考虑到疾病的异质性，我们利用骨肉瘤患者手术切除的肿瘤组织建立了一种新的细胞系nc - os2 - c1。NCC-OS2-C1细胞表现出持续的增殖、球状形成和侵袭。此外，我们证明了NCC-OS2-C1适用于药物的高通量筛选。因此，NCC-OS2-C1是骨肉瘤基础研究和转化研究的重要工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Human Cell CELL BIOLOGY-

CiteScore

5.90

自引率

2.30%

发文量

176

审稿时长

4.5 months

期刊介绍： Human Cell is the official English-language journal of the Japan Human Cell Society. The journal serves as a forum for international research on all aspects of the human cell, encompassing not only cell biology but also pathology, cytology, and oncology, including clinical oncology. Embryonic stem cells derived from animals, regenerative medicine using animal cells, and experimental animal models with implications for human diseases are covered as well. Submissions in any of the following categories will be considered: Research Articles, Cell Lines, Rapid Communications, Reviews, and Letters to the Editor. A brief clinical case report focusing on cellular responses to pathological insults in human studies may also be submitted as a Letter to the Editor in a concise and short format. Not only basic scientists but also gynecologists, oncologists, and other clinical scientists are welcome to submit work expressing new ideas or research using human cells.